Stephen Hauser, MD

Neurologist and immunologist

Dr. Stephen L. Hauser is a neurologist, internist and immunologist who specializes in multiple sclerosis. He is director of the UCSF Weill Institute for Neurosciences and an international leader in research on the genetic basis, immune mechanisms and treatment of MS. Hauser identified the benefit of immunosuppression to prevent the body from attacking the myelin sheath, the insulation surrounding nerves in the brain and spinal cord. He also demonstrated the benefit of MS treatments directed against B lymphocytes, a type of immune cell.

Hauser earned his medical degree at Harvard Medical School. He trained in internal medicine at New York–Presbyterian Hospital/Weill Cornell Medical Center, in neurology at Massachusetts General Hospital and in immunology at Harvard Medical School and the Institut Pasteur.

Hauser has received numerous awards and honors, including an appointment by President Barack Obama as an adviser on issues emerging from advances in biomedicine and related areas of science and technology. He is a fellow of the American Academy of Arts and Sciences and Association of American Physicians. and a member of the National Academy of Medicine. He is also a former president of the American Neurological Association and an editor of the textbook "Harrison's Principles of Internal Medicine."

Hauser is a professor of neurology at UCSF. He speaks French.

Clinics

Multiple Sclerosis Center
1500 Owens St., Suite 320
San Francisco, CA 94158
Phone: (415) 353-2069
Fax: (415) 353-2633

Hours: Monday to Friday
8 a.m. – 5 p.m.

Neurology Clinic
400 Parnassus Ave., Eighth Floor
San Francisco, CA 94143
Phone: (415) 353-2273
Fax: (415) 353-2898

Hours: Monday to Friday
8:30 a.m. – 4:30 p.m.

Academic Title

Professor

More about Stephen Hauser

Additional Languages

French

Education

Harvard University School of Medicine 1975

Residencies

New York–Presbyterian Hospital/Weill Cornell Medical Center, Internal Medicine 1978

Fellowships

Massachusetts General Hospital, Neurology 1980

Selected Research and Publications

  1. Prbstel AK, Hauser SL. Multiple Sclerosis: B Cells Take Center Stage. J Neuroophthalmol. 2018 Mar 20.
  2. Havrdov E, Arnold DL, Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G. No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Mult Scler J Exp Transl Clin. 2018 Jan-Mar; 4(1):2055217318760642.
  3. Canto E, Isobe N, Didonna A. Aberrant STAT phosphorylation signaling in peripheral blood mononuclear cells from multiple sclerosis patients. J Neuroinflammation. 2018 Mar 07; 15(1):72.
  4. Azevedo CJ, Cen SY, Khadka S, Liu S, Kornak J, Shi Y, Zheng L, Hauser SL, Pelletier D. Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease. Ann Neurol. 2018 Feb; 83(2):223-234.
  5. Sabatino JJ, Zamvil SS, Hauser SL. B-Cell Therapies in Multiple Sclerosis. Cold Spring Harb Perspect Med. 2018 Jan 22.
  6. Greenfield AL, Hauser SL. B-cell Therapy for Multiple Sclerosis: Entering an era. Ann Neurol. 2018 Jan; 83(1):13-26.
  7. Damotte V, Lize A, Tremblay M, Agrawal A, Khankhanian P, Santaniello A, Gomez R, Lincoln R, Tang W, Chen T, Lee N, Villoslada P, Hollenbach JA, Bevan CD, Graves J, Bove R, Goodin DS, Green AJ, Baranzini SE, Cree BA, Henry RG, Hauser SL, Gelfand JM, Gourraud PA. Harnessing electronic medical records to advance research on multiple sclerosis. Mult Scler. 2018 Jan 01; 1352458517747407.
  8. Graves JS, Henry RG, Cree BAC, Lambert-Messerlian G, Greenblatt RM, Waubant E, Cedars MI, Zhu A. Ovarian aging is associated with gray matter volume and disability in women with MS. Neurology. 2018 Jan 16; 90(3):e254-e260.
  9. Bove RM, Hauser SL. Diagnosing multiple sclerosis: art and science. Lancet Neurol. 2018 Feb; 17(2):109-111.
  10. Bischof A, Caverzasi E, Cordano C, Hauser SL, Henry RG. Advances in Imaging Multiple Sclerosis. Semin Neurol. 2017 Oct; 37(5):538-545.
  11. Eggers EL, Michel BA, Wu H, Wang SZ, Bevan CJ, Abounasr A, Pierson NS, Bischof A, Kazer M, Leitner E, Greenfield AL, Demuth S, Wilson MR, Henry RG, Cree BA, Hauser SL, von Bdingen HC. Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients. JCI Insight. 2017 Nov 16; 2(22).
  12. Gelfand JM, Bradshaw MJ, Stern BJ, Clifford DB, Wang Y, Cho TA, Koth LL, Hauser SL, Dierkhising J, Vu N, Sriram S, Moses H, Bagnato F, Kaufmann JA, Ammah DJ, Yohannes TH, Hamblin MJ, Venna N, Green AJ, Pawate S. Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series. Neurology. 2017 Nov 14; 89(20):2092-2100.
  13. Green AJ, Gelfand JM, Cree BA, Bevan C, Boscardin WJ, Mei F, Inman J, Arnow S, Devereux M, Abounasr A, Nobuta H, Zhu A, Friessen M, Gerona R, von Bdingen HC, Henry RG, Hauser SL, Chan JR. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet. 2017 Dec 02; 390(10111):2481-2489.
  14. Gelfand JM, Cree BAC, Hauser SL. Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis. Neurotherapeutics. 2017 Oct; 14(4):835-841.
  15. Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, Kanner R, Bencosme Y, Lee YK, Hauser SL, Crabtree-Hartman E, Sand IK, Gacias M, Zhu Y, Casaccia P, Cree BAC, Knight R, Mazmanian SK, Baranzini SE. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci U S A. 2017 Oct 03; 114(40):10713-10718.
  16. Hauser SL, VanLeeuwen J-E.. STAT [editorial]. 3 ways the VA can usher in the future of health care and research. 2017.
  17. Hauser SL, Belachew S, Kappos L. Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis. N Engl J Med. 2017 04 27; 376(17):1694.
  18. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017 01 19; 376(3):221-234.
  19. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017 01 19; 376(3):209-220.
  20. von Bdingen HC, Bischof A, Eggers EL, Wang S, Bevan CJ, Cree BA, Henry RG, Hauser SL. Onset of secondary progressive MS after long-term rituximab therapy - a case report. Ann Clin Transl Neurol. 2017 Jan; 4(1):46-52.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.